Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by F. Offner
Augment: Relapsed/Refractory Indolent NHL Patients Were More Sensitive to Next Treatment Following Lenalidomide/Rituximab (R2 ) Than Rituximab/Placebo
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Augment Phase Iii Study: Lenalidomide/Rituximab (R2 ) Improved Efficacy Over Rituximab/Placebo in Relapsed/Refractory Follicular Patients Irrespective of Pod24 Status
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Effect of Dose Modifications on Response to Duvelisib in Patients With Relapsed/Refractory CLL/SLL in the Duo Trial
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Characterization of Duvelisib in Patients With Refractory Marginal Zone Lymphoma: Data From the Phase 2 Dynamo Trial
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
HEALTH-RELATED QUALITY OF LIFE (HRQoL) IN RELAPSED/REFRACTORY (R/R) INDOLENT NHL IN THE PHASE 3 AUGMENT TRIAL OF RITUXIMAB (R) PLUS LENALIDOMIDE (R2 ) VERSUS R PLUS PLACEBO
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Post Hoc Analyses of Patients With Relapsed/Refractory Marginal Zone Lymphoma Who Received Lenalidomide Plus Rituximab (R2 ) vs Rituximab/Placebo (Augment)
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
